Aldeyra (ALDX) announced that the European Medicines Agency has granted orphan designation for ADX-2191 for the treatment of primary large B-Cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphoma. There is currently no approved treatment for patients with primary vitreoretinal lymphoma, a rare, aggressive, high-grade cancer that affects approximately 100 to 200 people per year in the European Union.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- Aldeyra Therapeutics Gains FDA Fast Track for ADX-2191
- Aldeyra granted fast track designation for ADX-2191 by FDA
- Aldeyra Therapeutics: Positive NDA Resubmission and Strategic Advancements Support Buy Rating
- Buy Rating for Aldeyra Therapeutics Driven by FDA Progress and Strategic Partnership Potential
- Aldeyra receives orphan designation for ADX-2191 from EMA